Amazon Explores AI Content Marketplace With Media Publishers 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
NEW YORK, Nov. 14, 2017 -- PHI Group, Inc., (www.phiglobal.com) (OTCQB:PHIL), a company focused on mergers and acquisitions and investments in selective industries, announced today that its wholly owned subsidiary Phivitae Corporation has signed a Business Cooperation Agreement with a Lao company to provide pharmaceutical products, medical equipment and healthcare supplies to Laos.
According to the Agreement, Phivitae Corp. will be responsible for identifying and forming strategic alliance with reputable international manufacturers and suppliers in North America, European Union and India to provide pharmaceutical products, medical equipment and healthcare supplies that meet or exceed international required standards to Laos and its neighboring markets. The term of the Agreement is for six years and may be renewed every five years thereafter by mutual consent of both parties.
As previously announced, the Company has signed a letter of intent to acquire 80% of a 20-year old profitable European company that is engaged in pharmaceutical and medical device distribution in Eastern Europe. The target company can serve as a platform to provide Western pharmaceutical products from Europe to Laos and also distribute prized organic medicines developed by Tho Xuan Duong JSC, a company recognized by Guinness World Records with nearly four centuries of history in Vietnamese traditional medicine and herbs (www.thoxuanduong.com), to European and Middle Eastern markets.
Henry Fahman, CEO of PHI Group, said, “We are delighted to work with our Lao partner to provide much needed high quality pharmaceutical products and medical equipment to Laos and its neighboring markets. This will help serve the healthcare needs of the Lao people and also provide a great business opportunity for our partner and us.”
About PHI Group
PHI Group (www.phiglobal.com) primarily focuses on mergers and acquisitions and invests in select industries and special situations that may substantially enhance shareholder value. PHI Group also provides M&A and consulting services through its wholly owned subsidiary, PHI Capital Holdings, Inc. (www.phicapitalholdings.com).
About Phivitae Corporation
Phivitae Corporation, a Wyoming corporation, is a wholly owned subsidiary of PHI Group, Inc. set up to manage the Company’s healthcare-related businesses.
Safe Harbor
This news release contains forward-looking statements that are subject to certain risks and uncertainties that may cause actual results to differ materially from those projected on the basis of such forward-looking statements pursuant to the “safe-harbor” provisions of the Private Securities Litigation Reform Act of 1995.
Press Contact:
Henry Fahman
+1-702-475-5430
[email protected]
